Search research articles

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The changing epidemiology of <i>Candida</i> species in Asia Pacific and evidence for optimizing antifungal dosing in challenging clinical scenarios.

Expert review of anti-infective therapy·2025

Same author

Correction: Tegileridine: First Approval.

Drugs·2024

Same author

Ivonescimab: First Approval.

Drugs·2024

Same author

Tarlatamab: First Approval.

Drugs·2024

Same author

Tovorafenib: First Approval.

Drugs·2024

Same author

Zevorcabtagene Autoleucel: First Approval.

Molecular diagnosis & therapy·2024

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Video

Updated: Nov 6, 2025

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

Melphalan Flufenamide (Melflufen): First Approval.

Sohita Dhillon¹

¹Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.

|May 7, 2021

Summary

Melphalan flufenamide is a novel peptide-conjugated alkylating drug approved for treating relapsed or refractory multiple myeloma. Its unique delivery mechanism enhances efficacy against cancer cells.

Area of Science:

Oncology
Pharmacology
Drug Development

Background:

Melphalan flufenamide (melflufen) is a peptide-conjugated alkylating agent.
It is designed for targeted delivery and intracellular activation.

Purpose of the Study:

To summarize the development milestones of melphalan flufenamide.
To highlight its first regulatory approval for multiple myeloma.

Main Methods:

Review of preclinical and clinical development data.
Analysis of regulatory submission and approval process.

Main Results:

Melphalan flufenamide received US FDA approval in February 2021.
Approval was for adults with relapsed/refractory multiple myeloma after multiple prior therapies.

More Related Videos

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Published on: January 25, 2015

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

Related Experiment Videos

Last Updated: Nov 6, 2025

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Published on: January 25, 2015

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

Conclusions:

Melphalan flufenamide represents a significant advancement in multiple myeloma treatment.
Ongoing studies are exploring its potential in amyloid light-chain amyloidosis and other cancers.